{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:19:23Z","timestamp":1790313563931,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nanjing Medical Technology Development Project","award":["YKK14079"],"award-info":[{"award-number":["YKK14079"]}]},{"name":"Jiangsu Provincial Science and Technology Department","award":["BE2012606"],"award-info":[{"award-number":["BE2012606"]}]},{"name":"National Health and Family Planning Commission, Science and Education Department","award":["201502004"],"award-info":[{"award-number":["201502004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To examine differences in the plasma levels of miRNA-21, \u2212\u2009214, \u221234a, and -200a in patients with persistent high-risk human papillomavirus (hr-HPV) infection or with cervical lesions of different grades.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Venous blood was collected from 232 individuals to measure the plasma expression levels of miRNA-21, \u2212\u2009214, \u221234a, and -200a. The subjects included normal controls and patients with persistent hr-HPV infection, CIN1, CIN2, CIN3, or cervical cancer (n\u2009=\u200942, 31, 19, 54, 71, and 15 patients, respectively). Cervical conization specimens were collected from all the women. To ensure the accuracy of histopathology, three consecutive tissue sections with an identical diagnosis were selected, and dissection samples were taken from them for miRNA detection. Eligible cases met the inclusion criteria based on sample observation using the middle slice of sandwich tissue sections from the pathological tissue in accordance with the diagnosis of CIN1, CIN2 and CIN3 in 8, 29, and 26 cases, respectively. The miRNA-21, \u2212\u2009214, \u221234a, and -200a expression levels in the paraffin-embedded tissue samples were determined. The percentage of patients with a CIN2+ diagnosis at 30\u201349\u2009years old was significantly different from that of those diagnosed with CIN1. The incidence of CIN2+ patients exposed to passive smoking was significantly different from that of CIN1- patients. The percentage of CIN2+ patients with three pregnancies was significantly different from that of those with CIN1, and the percentage of CIN2+ subjects with \u22654 pregnancies was significantly different from that of CIN1- patients. The number of CIN2+ patients with two or more induced abortions was significantly different from that of patients with CIN1. The percentage of CIN2+ patients who underwent a caesarean section was significantly different from that of patients with CIN. The percentage of CIN2+ patients with first-degree relatives with cancer was significantly different from that of those with CIN1. Among CIN2+ patients, the percentage with a first sexual encounter at \u226420\u2009years old was significantly different from that of those with CIN1. The percentage of CIN2+ patients with \u22652 sexual partners was significantly different from that of CIN1- patients.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The plasma miRNA-214, \u221234a, and -200a expression levels were decreased in patients with more severe cervical lesions. Plasma miRNA levels in CIN1- patients were significantly different from those in CIN2+ patients. The kappa values for miRNA-21, \u2212\u2009214, \u221234a and -200a in tissue versus plasma were 0.7122, 0.9998, 0.8986 and 0.7458, respectively. The sensitivity of each biomarker for detecting CIN2 was calculated, and ROC curves of the four miRNA biomarkers were drawn. The AUC of the four plasma miRNAs was greater than 0.5, with the AUC of miRNA-21 being the largest at 0.703. The plasma miRNA expression levels exhibited at least one tie between CIN1 and CIN2. The AUCs for miRNA-21, \u221234a, \u2212200a and\u2009\u2212\u2009214 were 0.613, 0.508, 0.615 and 0.505, respectively.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Changes in plasma miRNA-21, \u2212\u2009214, \u221234a and -200a levels were associated with cervical lesion severity. The plasma miRNA levels in CIN1- subjects were significantly different from those in CIN2+ subjects. This analysis may help in detection of high-grade cervical lesions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6066-6","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T10:57:02Z","timestamp":1571828222000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Plasma expression of miRNA-21, \u2212\u2009214, \u221234a, and -200a in patients with persistent HPV infection and cervical lesions"],"prefix":"10.1186","volume":"19","author":[{"given":"Hongyun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8727-8248","authenticated-orcid":false,"given":"Ying","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"issue":"3","key":"6066_CR1","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1002\/jcp.26019","volume":"233","author":"A Bahrami","year":"2018","unstructured":"Bahrami A, Hasanzadeh M, Shahidsales S, et al. Genetic susceptibility in cervical cancer: from bench to bedside. J Cell Physiol. 2018;233(3):1929\u201339.","journal-title":"J Cell Physiol"},{"key":"6066_CR2","first-page":"1675","volume":"6","author":"Q Cheng","year":"2013","unstructured":"Cheng Q, Yi B, Wang A, et al. Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. OncoTargets Ther. 2013;6:1675\u201384 \n                    https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Exploring\u00b1and\u00b1exploiting\u00b1the\u00b1fundamental\u00b1role\u00b1of\u00b1microRNAs\u00b1in\u00b1tumor\u00b1pathogenesis\n                    \n                  .","journal-title":"OncoTargets Ther"},{"key":"6066_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/138920209788185252","volume":"10","author":"O Maes","year":"2009","unstructured":"Maes O, Chertkow H, Wang E, et al. MicroRNA: implications for Alzheimer disease and other human CNS disorders. Curr Genomics. 2009;10:154\u201368.","journal-title":"Curr Genomics"},{"key":"6066_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2174\/22115366113029990015","volume":"2","author":"N Nouraee","year":"2013","unstructured":"Nouraee N, Calin GA. MicroRNAs as Cancer biomarkers. MiR. 2013;2:102\u201317.","journal-title":"MiR"},{"key":"6066_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s12253-014-9871-x","volume":"21","author":"A Galamb","year":"2015","unstructured":"Galamb A, Benczik M, Zinner B, et al. Dysregulation of microRNA expression in human cervical preneoplastic and neoplastic lesions. Pathol Oncol Res. 2015;21:503\u20138.","journal-title":"Pathol Oncol Res"},{"key":"6066_CR6","doi-asserted-by":"publisher","first-page":"e0164701","DOI":"10.1371\/journal.pone.0164701","volume":"11","author":"D Gao","year":"2016","unstructured":"Gao D, Zhang Y, Zhu M, Liu S, et al. MiRNA expression profiles of HPV-infected patients with cervical Cancer in the Uyghur population in China. PLoS One. 2016;11:e0164701.","journal-title":"PLoS One"},{"key":"6066_CR7","first-page":"2442","volume":"13","author":"XY Xu","year":"2014","unstructured":"Xu XY, Hong Y. The preliminary experiment research of correlation between plasma miRNA expression spectrum and cervical cancer. Chin J Clinicians (Electronic Edition). 2014;13:2442\u20137 \n                    http:\/\/kns.cnki.net\/KCMS\/detail\/detail.aspx?dbcode=CJFQ&dbname=CJFD2014&filename=ZLYD201413017&v=MDE4MzBoMVQzcVRyV00xRnJDVVJMT2ZZT1J1RnlubFZMekpQeUhTYXJHNEg5WE5ySTlFWTRSOGVYMUx1eFlTN0Q=\n                    \n                  .","journal-title":"Chin J Clinicians (Electronic Edition)"},{"issue":"8","key":"6066_CR8","first-page":"1037","volume":"22","author":"W You","year":"2015","unstructured":"You W, Wang Y, Zheng J. Plasma miR-127 and miR-218 might serve as potential biomarkers for cervical Cancer [J]. ReprodSci. 2015;22(8):1037\u201341.","journal-title":"ReprodSci"},{"key":"6066_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-016-2231-3","volume":"16","author":"O Peralta-Zaragoza","year":"2016","unstructured":"Peralta-Zaragoza O, Deas J, Meneses-Acosta A, et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells [J]. BMC Cancer. 2016;16:215.","journal-title":"BMC Cancer"},{"key":"6066_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12935-017-0431-9","volume":"17","author":"AH Chen","year":"2017","unstructured":"Chen AH, Qin YE, Tang WF, et al. MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer. Cancer Cell In. 2017;17:63.","journal-title":"Cancer Cell In"},{"key":"6066_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2017.01.152","volume":"484","author":"R Peng","year":"2017","unstructured":"Peng R, Men J, Ma R, et al. MiR-214 down-regulates ARL2 and suppresses growth and invasion of cervical cancer cells. Biochem Biophys Res Commun. 2017;484:623\u201330.","journal-title":"Biochem Biophys Res Commun"},{"key":"6066_CR12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/ijc.29618","volume":"138","author":"Y He","year":"2016","unstructured":"He Y, Lin J, Ding Y, et al. A systematic study on dysregulated microRNAs in cervical cancer development. Int J Cancer. 2016;138:1312\u201327.","journal-title":"Int J Cancer"},{"key":"6066_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/IGC.0b013e3181d63170","volume":"20","author":"B Li","year":"2010","unstructured":"Li B, Hu Y, Ye F, et al. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int J Gynecol Cancer. 2010;20:597\u2013604.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"6066_CR14","first-page":"355","volume":"10","author":"L Nambaru","year":"2009","unstructured":"Nambaru L, Meenakumari B, Swaminathan R, et al. Prognostic significance of HPV physical status and integration sites in cervical cancer [J]. Asian Pac J Cancer Prev. 2009;10(3):355\u201360 \n                    https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Prognostic\u00b1significance\u00b1of\u00b1HPV\u00b1physical\u00b1status\u00b1and\u00b1integration\u00b1sites\u00b1in\u00b1cervical\u00b1cancer\n                    \n                  .","journal-title":"Asian Pac J Cancer Prev"},{"issue":"12","key":"6066_CR15","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1073\/pnas.1019055108","volume":"108","author":"JD Arroyo","year":"2011","unstructured":"Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci. 2011;108(12):5003\u20138.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"6066_CR16","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3892\/ijo.2012.1647","volume":"41","author":"A Allegra","year":"2012","unstructured":"Allegra A, Alonci A, Campo S, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012;41(6):1897\u2013912.","journal-title":"Int J Oncol"},{"issue":"2","key":"6066_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/med.20215","volume":"32","author":"K Zen","year":"2012","unstructured":"Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32(2):326\u201348.","journal-title":"Med Res Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6066-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6066-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6066-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T23:04:35Z","timestamp":1603321475000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6066-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6066"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6066-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the clinical research ethics committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School (22 March 2014). Written, informed consent was provided by all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript does not contain any individual person\u2019s data in any form. This paper has not been published elsewhere in whole or in part. Our manuscript does not contain any individual person\u2019s data, and thus, the \u2018Consent for publication\u2019 section is not applicable.All authors have read and approved the manuscript content and agreed to submission of the manuscript for consideration for publication in the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no ethical\/legal conflicts associated with this article. The authors declare that they have no competing financial relationships or conflicts of interest associated with the subject matter or the materials discussed in the manuscript apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"986"}}